OSE Immunotherapeutics SA (OSE.PA)
Develops cancer and inflammation treatments using immunotherapy approaches.
3.17-0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-49.6%
The outlook
OSE trades well below both its 50- and 200-day moving averages, sitting near the bottom of its 52-week range. Analyst targets average around 301% above the current price, though coverage leans bearish overall. The stock remains in a downtrend by most intermediate measures.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range6% of the way from its 52-week low to high
Price targetAvg target +301% vs current price
Analyst price target
~12-month · 4 analysts12.70average target+301.1% vs now
Now 3.17
Low 8.20High 21.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$74.9M
52-wk high
7.70
52-wk low
2.87
50-day avg
3.71
200-day avg
4.35
Trailing P/E
—